# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Single Technology Appraisal (STA)**

# Mifamurtide for osteosarcoma

### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
<ul> <li>IDM Pharma (mifamurtide)</li> <li>Patient/carer groups</li> <li>Action for Sick Children</li> <li>Adam Dealey Foundation for Ewing Sarcoma</li> <li>Afiya Trust</li> <li>Age Concern England</li> <li>Anthony Pilcher Bone Cancer Trust</li> <li>Association for Children with Life Threatening or Terminal Conditions</li> </ul>	<ul> <li>Age Concern Cymru</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Cancer Care Cymru</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Public Health Service for Wales</li> </ul>
<ul> <li>Black Health Agency</li> <li>Bone Cancer Research Trust</li> <li>British Ethnic Health Awareness Foundation</li> <li>CANCERactive</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> </ul>	<ul> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>NHS Purchasing and Supply Agency</li> <li>NHS Quality Improvement Scotland</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Cancer Voices</li> <li>Cancerbackup</li> <li>Children's Society</li> <li>Chinese National Healthy Living Centre</li> <li>CLIC Sargent</li> <li>Confederation of Indian Organisations</li> <li>Counsel and Care</li> <li>Equalities National Council</li> <li>Help Adolescents with Cancer</li> <li>Help the Aged</li> <li>Leonard Cheshire Disability</li> <li>Limbless Association</li> </ul>	<ul> <li>Comparator manufacturer(s)</li> <li>Baxter Healthcare (ifosfamide)</li> <li>Cephalon UK (doxorubicin)</li> <li>Goldshield Pharmaceuticals (methotrexate)</li> <li>Hospira UK (cisplatin, doxorubicin, methotrexate)</li> <li>Medac (doxorubicin)</li> <li>Pfizer (cisplatin, doxorubicin)</li> <li>Teva UK (cisplatin, methotrexate)</li> <li>Wockhardt UK (cisplatin, doxorubicin, methotrexate)</li> <li>Wyeth Pharmaceuticals (methotrexate)</li> </ul>
<ul> <li>Limb Loss Information Centre</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie Cancer Care</li> </ul>	Relevant research groups  Bone Research Society Christopher Hardman Osteosarcoma

National Institute for Health and Clinical Excellence Matrix for the appraisal of mifamurtide for osteosarcoma Issue date: August 2008

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Muslim Council of Great Britain</li> <li>Muslim Health Network</li> <li>National Alliance of Childhood Cancer Patient Organisations</li> <li>National Association for the Relief of Paget's Disease</li> <li>National Cancer Alliance</li> <li>National Children's Bureau</li> <li>National Council for Palliative Care</li> <li>NCH – The Children's Charity</li> <li>RADAR - Royal Association for Disability &amp; Rehabilitation</li> <li>Rarer Cancers Forum</li> <li>Sarcoma UK</li> <li>Skill: National Bureau for Students with Disabilities</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Steps</li> <li>Sue Ryder Care</li> </ul>	<ul> <li>Research Fund</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Cancer Research Institute</li> <li>National Cancer Research Network</li> <li>Policy Research Institute on Ageing and Ethnicity</li> <li>Research Institute for the Care of Older People</li> <li>Evidence Review Group</li> <li>School of Health &amp; Related Research Sheffield (ScHARR)</li> <li>National Coordinating Centre for Health Technology Assessment</li> <li>Associated Guideline Groups</li> <li>National Collaborating Centre for Women and Children</li> <li>National Collaborating Centre for Cancer</li> </ul>
<ul><li>Teenage Cancer Trust</li><li>Tenovus Cancer Information Centre</li><li>WellChild</li></ul>	Associated Public Health Groups  None
<ul> <li>Professional groups</li> <li>Association of Cancer Physicians</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>British Association for Services to the Elderly</li> <li>British Association of Surgical Oncology</li> <li>British Institute of Musculoskeletal Medicine</li> <li>British Oncological Association</li> <li>British Orthopaedic Association</li> <li>British Orthopaedic Oncology Society</li> <li>British Psychosocial Oncology Society</li> <li>British Sarcoma Group</li> <li>British Society of Rehabilitation Medicine</li> <li>Cancer Networks Pharmacists Forum</li> <li>Cancer Research UK</li> <li>Children's Cancer and Leukaemia</li> </ul>	

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Group</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatric and Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>United Kingdom Oncology Nursing Society</li> <li>Vascular Society</li> </ul>	
Others  Department of Health Sheffield PCT Welsh Assembly Government West Sussex Teaching PCT	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

#### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Matrix for the appraisal of mifamurtide for osteosarcoma Issue date: August 2008

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.